Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002)
- PMID: 16609990
- PMCID: PMC4087509
- DOI: 10.3748/wjg.v12.i12.1849
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002)
Abstract
Aim: To evaluate the long-term outcome of standard 5-FU based adjuvant or neoadjuvant radiochemotherapy and to identify the predictive factors, especially anemia before and after radiotherapy as well as hemoglobin increase or decrease during radiotherapy.
Methods: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002. Overall survival (OAS), cancer-specific survival (CSS), disease-free survival (DFS), local-relapse-free (LRS) and distant-relapse-free survival (DRS) were evaluated using Kaplan-Meier, Log-rank test and Cox's proportional hazards as statistical methods. Multivariate analysis was used to identify prognostic factors. Median follow-up time was 8 years.
Results: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender. The univariate analysis revealed that anemia was associated with impaired LRS (better local control) but with improved DFS. In contrast, hemoglobin decrease during radiotherapy was an independent risk factor for DFS (risk ratio 1.97, P=0.04). During radiotherapy, only 30.8% of R0-resected patients suffered from hemoglobin decrease compared to 55.6% if R1/2 resection was performed (P=0.04). The 5-year OAS, CSS, DFS, LRS and DRS were 47.0%, 60.0%, 41.4%, 67.2%, and 84.3%, respectively. Significant differences between preoperative and postoperative radiochemotherapy were not found.
Conclusion: Anemia before radiochemotherapy and hemoglobin decrease during radiotherapy have no predictive value for the outcome of rectal cancer. Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.
Figures
Similar articles
-
Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9.Anticancer Res. 2005 May-Jun;25(3A):1787-93. Anticancer Res. 2005. PMID: 16033101
-
Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.Dis Colon Rectum. 2004 Nov;47(11):1798-807. doi: 10.1007/s10350-004-0681-1. Dis Colon Rectum. 2004. PMID: 15622571
-
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?World J Surg Oncol. 2010 Apr 13;8:27. doi: 10.1186/1477-7819-8-27. World J Surg Oncol. 2010. PMID: 20388220 Free PMC article.
-
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].Cancer Radiother. 2011 Oct;15(6-7):440-4. doi: 10.1016/j.canrad.2011.05.006. Epub 2011 Jul 28. Cancer Radiother. 2011. PMID: 21802334 Review. French.
-
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Int J Radiat Oncol Biol Phys. 2009. PMID: 19735864 Review.
Cited by
-
Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience.Clin Transl Oncol. 2012 Jun;14(6):471-80. doi: 10.1007/s12094-012-0826-y. Clin Transl Oncol. 2012. PMID: 22634537
-
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.J Cancer Res Clin Oncol. 2010 Feb;136(2):283-92. doi: 10.1007/s00432-009-0660-y. Epub 2009 Aug 20. J Cancer Res Clin Oncol. 2010. PMID: 19693536 Free PMC article.
-
Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival.Sci Rep. 2018 Jan 18;8(1):1126. doi: 10.1038/s41598-018-19572-y. Sci Rep. 2018. PMID: 29348549 Free PMC article.
References
-
- Saltz LB, Minsky B. Adjuvant therapy of cancers of the colon and rectum. Surg Clin North Am. 2002;82:1035–1058. - PubMed
-
- Kachnic LA, Willett CG. Radiation therapy in the management of rectal cancer. Curr Opin Oncol. 2001;13:300–306. - PubMed
-
- Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. J Clin Oncol. 1992;10:549–557. - PubMed
-
- Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–715. - PubMed
-
- Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol. 2004;180:45–51. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical